TCMD — what changed in the latest 10-Q
A section-by-section comparison of TCMD's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-11-02 vs the prior 10-Q · 2026-08-10
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +9 | −7 | ~29 | 24 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 0 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
| Other information | Text added/removed | +17 | −1 | 0 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3)
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-11-02
Gross margin was 77% and 76% in the three months ended September 30, 2026 and 2025, respectively, and 77% and 75% in the nine months ended September 30, 2026 and 2025, respectively.
Sales and marketing expenses increased $3.2 million, or 11%, to $33.0 million in the three months ended September 30, 2026, compared to $29.8 million in the three months ended September 30, 2025. The increase was primarily attributable to a $2.9 million increase in personnel-related compensation exp…
(including travel and entertainment expenses) and a $0.6 million increase in expenses for meetings and seminars.
Sales and marketing expenses increased $10.4 million, or 12%, to $97.8 million in the nine months ended September 30, 2026, compared to $87.4 million in the nine months ended September 30, 2025. The increase was primarily attributable to a $9.7 million increase in personnel-related compensation expe…
R&D expenses increased $1.8 million, or 31%, to $7.8 million in the nine months ended September 30, 2026, compared to $6.0 million in the nine months ended September 30, 2025. The increase was primarily attributable to a $0.8 million increase in personnel-related compensation expenses and a $0.7 mil…
Text removed vs the prior filing · source: 10-Q · 2026-08-10
Sales and marketing expenses increased $2.0 million, or 7%, to $32.0 million in the three months ended June 30, 2026, compared to $30.0 million in the three months ended June 30, 2025. The increase was primarily attributable to a $2.9 million increase in personnel-related compensation expenses (incl…
entertainment expenses) and a $0.2 million increase in expenses for professional services, partially offset by a $1.4 million decrease in expenses related to meetings and seminars.
Sales and marketing expenses increased $7.2 million, or 12%, to $64.7 million in the six months ended June 30, 2026, compared to $57.6 million in the six months ended June 30, 2025. The increase was primarily attributable to a $6.8 million increase in personnel-related compensation expenses, a $0.2 …
Research and development (“R&D”) expenses increased $0.5 million, or 24%, to $2.5 million in the three months ended June 30, 2026, compared to $2.0 million in the three months ended June 30, 2025. The increase was primarily attributable to a $0.2 million increase in IT-related expenses and a $0.2 mi…
Interest income decreased $0.5 million, or 30%, to $1.2 million in the six months ended June 30, 2026, compared to $1.7 million in the six months ended June 30, 2025, primarily due to a lower cash balance in an Institutional Insured Liquid Deposit demand account due to funds being utilized for the L…
Other information
Text added vs the prior filing · source: 10-Q · 2026-11-02
On September 17, 2026, Laura G. King, a member of our Board of Directors, adopted a pre-arranged trading plan that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act. This plan provides for the sale of up to 6,521 shares of our common stock, plus up to an additional…
On September 18, 2026, D. Brent Shafer, a member of our Board of Directors, adopted a pre-arranged trading plan that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act. This plan provides for the sale of up to 6,521 shares of our common stock in the aggregate and te…
Because we are filing this Quarterly Report on Form 10-Q within four business days after the triggering event, we are making the following disclosure under this Item 5 instead of filing a Current Report on Form 8-K under Item 5.02, Departure of Directors or Certain Officers; Election of Directors; A…
On November 2, 2026, the Company announced that its Board of Directors has appointed Stephen A. Kiewiet to the office of Chief Operating Officer of the Company, effective November 2, 2026.
Prior to joining the Company, Mr. Kiewiet, age 58, served in various executive roles at CCS Medical, a chronic care management organization, including Chief Growth Officer from September 2025 to August 2026, Chief Commercial Officer from January 2024 to September 2025, and Chief Operating Officer fr…
Text removed vs the prior filing · source: 10-Q · 2026-08-10
During the quarter ended June 30, 2026, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Ru…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice